Ganciclovir prophylaxis in CMV high-risk renal transplant recipients.

被引：0
|
作者：
Kletzmayr, J [1 ]
Safar, T [1 ]
Kovarik, J [1 ]
Klauser, R [1 ]
机构：
[1] UNIV VIENNA, DEPT NEPHROL & DIALYSIS, A-1010 VIENNA, AUSTRIA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 1997年 / 8卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A3210 / A3210
页数：1
相关论文
共 50 条
  • [21] Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients
    Brady, R. L.
    Green, K.
    Frei, C.
    Maxwell, P.
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (02) : 106 - 111
  • [22] Valgan (ganciclovir hydrochloride) provides ineffective prophylaxis against cytomegaloviral (CMV) infection in liver transplant recipients.
    Jain, A
    Orloff, M
    Lansing, K
    Kashyap, R
    Kelley, M
    Betts, R
    Menegus, M
    Adel, B
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 569 - 569
  • [23] Pre-Transplant Ganciclovir and High-Dose Valacyclovir Prophylaxis Decrease Incidence of CMV Reactivation In High-Risk Seropositive UCBT Recipients
    Milano, Filippo
    Pergam, Steven
    Xie, Hu
    Gutman, Jonathan
    Riffkin, Ivy
    Chow, Victor
    Newell, Laura
    Boeckh, Michael
    Delaney, Colleen
    [J]. BLOOD, 2010, 116 (21) : 298 - 298
  • [24] Impact of Prolonging CMV Prophylaxis in High-Risk (CMV D plus /R-) Lung Transplant Recipients
    Herrera, S.
    Khan, B.
    Husain, S.
    Binnie, M.
    Chow, C.
    Martinu, T.
    Chaparro, C.
    Keshavjee, S.
    Singer, L. G.
    Tikkanen, J.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S120 - S120
  • [25] Randomized trial of oral ganciclovir plus cytomegalovirus (CMV) immune globulin (Ig) versus oral ganciclovir alone for CMV prophylaxis in liver and kidney transplant recipients.
    Johnson, M
    Zacks, S
    McIver, P
    Russo, M
    Dupuis, R
    Andreoni, K
    Gerber, D
    Malat, G
    Salm, J
    Shrestha, R
    Fair, J
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 535 - 535
  • [26] CMV PROPHYLAXIS WITH FOSCARNET IN ALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS AT HIGH-RISK OF DEVELOPING CMV INFECTIONS
    BACIGALUPO, A
    TEDONE, E
    VANLINT, MT
    TRESPI, G
    LONNGREN, M
    SANNA, MA
    MORO, F
    FRASSONI, F
    OCCHINI, D
    GUALANDI, F
    LAMPARELLI, T
    FIGARI, O
    BENVENUTO, F
    RAFFO, MR
    SOGNO, G
    ISAZA, A
    DINEGRO, GB
    FELLETTI, R
    HALE, G
    MARMONT, AM
    [J]. BONE MARROW TRANSPLANTATION, 1994, 13 (06) : 783 - 788
  • [27] Superior cytomegalovirus prophylaxis with oral ganciclovir compared to oral acyclovir in pediatric renal, transplant recipients.
    Smith, L
    Somerville, T
    Sherbotie, J
    Shihab, F
    Holman, J
    [J]. TRANSPLANTATION, 2000, 69 (08) : S307 - S307
  • [28] Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients
    Kletzmayr, J
    Kreuzwieser, E
    Watkins-Riedel, T
    Berlakovich, G
    Kovarik, J
    Klauser, R
    [J]. TRANSPLANTATION, 2000, 70 (08) : 1174 - 1180
  • [29] Incidence of CMV Disease in High-Risk Liver Transplant Recipients on Low Dose Valganciclovir Prophylaxis
    Tischer, S.
    Park, J.
    Stuckey, L.
    Kaul, D.
    Sonnenday, C.
    Fontana, R.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 221 - 222
  • [30] A simplified strategy for clinical management of late cytomegalovirus (CMV) infection after oral ganciclovir prophylaxis in renal recipients.
    Kuypers, DR
    Claes, K
    Evenepoel, P
    Maes, B
    Vanrenterghem, Y
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 168 - 168
12345